HER2-antigen specific cancer vaccine

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHER2-antigen specific cancer vaccine

Drug Alias NamedHER2+AS15 ASCI,HER2-antigen specific cancer immunotherapeuticHER2抗原特异性肿瘤疫苗dHER2+AS15HER2-ASCI

ClassificationVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulantsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

ATC CodeN/A